AEON Biopharma, Inc. (AEON)
AEON Biopharma is developing ABP-450, a botulinum toxin meant to be a biosimilar to Botox for therapeutic uses. It last closed at $0.12 on Nov 17, down 15.59% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From AEON's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on AEON in the past 90 days. The average target is $2.00, with a high of $2.00 and a low of $2.00, compared with the last close of $0.12.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 1 | Lake Street | Maintained | Buy | $2 |
| Aug 14 | HC Wainwright & Co. | Maintained | Buy | $1.20 |
Technical Analysis
The stock is 76% below its 20 day and 104% below its 50 day average. It is 418% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $0.11, and the nearest resistance the Pivot at $0.13.
| RSI (14) | 27.91 | Oversold below 30 | Oversold |
| MACD | -0.03 | Below its signal line | Bearish |
| Stochastic | 10.2 | Near the bottom of its range | Oversold |
| ADX (14) | 27.5 | Trending down | |
| Williams %R | -94.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -125.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −43.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.03 | Typical daily range, 25.3% of price |
| RSI (14) | 31.69 | Weak, oversold below 30 | Neutral |
| MACD | -0.19 | Above its signal line | Bullish |
| Stochastic | 10.4 | Near the bottom of its range | Oversold |
| ADX (14) | 20.7 | Weak trend | |
| Williams %R | -96.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -197.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −63.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.14 | Typical daily range, 114.5% of price |
What happened before
See how AEON did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How AEON has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in AEON in the last 90 days.
AEON Institutional Ownership
Full report →- ▲13 buying vs 5 selling
- ▲Held by funds +58.8 pts
- ▲Funds holding +6
- ▲Superinvestors: 1 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 28 | 22 | +27.3% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 74.0% | 15.2% | +58.8 pts |
| New / increased | 10 / 3 | 2 / 6 | +62.5% |
| Reduced / sold out | 1 / 4 | 1 / 4 | 0.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AEON is in one of them and how their past AEON trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AEON in an article yet. Here's the latest on the wider market.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company based in Aliso Viejo, California. It is developing ABP-450, a botulinum toxin intended to serve as a biosimilar to Botox for therapeutic medical uses rather than cosmetic ones. The product is still in development, and the company is working toward a regulatory filing in the United States. Its intended customers are physicians and patients who use botulinum toxin treatments for medical conditions.
- Headquarters
- Aliso Viejo, CA
